patent.fyi
Applications  /  US 2026/0355268
United States Patent Application Publication

US 2026/0355268 A1

Published
Nov 12, 2026
Filed
May 13, 2026
Earliest date on the face
Jan 31, 2018
Classification
A61K 35/76
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Support after documented progression

What ifWhat if the additional agent is reserved for documented progression after cell infusion?
Claim language“is about to receive”

Follow-up imaging measures tumor burden against a pretreatment baseline. Documented progression triggers review and selection of a nonviral treatment based on the tumor type.

1.2Direct interleukin protein delivery

What ifWhat if purified interleukin-2 protein supplies the cytokine signal directly?
Claim language“a virus comprising a nucleic acid molecule”

An aqueous infusion delivers recombinant interleukin-2 as a protein. The protein binds interleukin-2 receptors on responsive immune cells and activates intracellular signaling.

1.3Separate protein formulations

What ifWhat if two separate protein formulations supply the two cytokines directly?
Claim language“a first virus”

One formulation contains purified tumor necrosis factor alpha, and the other contains purified interleukin-2. Separate containers allow each protein to be prepared and administered independently.

1.4Direct interleukin seven delivery

What ifWhat if purified interleukin-7 protein supplies the cytokine signal directly?
Claim language“a virus comprising a nucleic acid molecule”

A buffered aqueous formulation carries recombinant interleukin-7. The protein binds the interleukin-7 receptor on responsive T cells and activates signaling that supports cell survival.

1.5Independently administered cytokine proteins

What ifWhat if separate protein formulations supply interleukin-7 and interleukin-2?
Claim language“a first virus”

One formulation contains recombinant interleukin-7, and the other contains recombinant interleukin-2. Each protein engages its corresponding receptor, and separate administrations allow independent scheduling.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Simulated combination therapy for training

A clinical training simulator represents the mesothelin-directed cell therapy and the cytokine-vector therapy as separate mock orders. Trainees reconcile patient identifiers and record simulated handoffs for both orders. The simulator compares the entries with a scripted case and flags missing records or mismatched identifiers.

Component substitution

Alginate beads as target surrogates

Mesothelin-coated alginate beads replace intact target cells in a receptor-binding demonstration. The beads sit in wells with fluorescently labeled soluble receptor fragments. A plate reader measures fluorescence retained after washing, and uncoated beads provide a background measurement.

Parameter or scale variation

Two plate sizes for binding

A bead-based mesothelin binding assay runs in either 96-well or 384-well plates. Each layout assigns four wells to mesothelin-coated beads and four wells to uncoated controls per sample. The reader reports the difference between mean coated and uncoated fluorescence for each sample.

Combination with existing systems

Separate inventory records for therapy components

A hospital inventory system maintains separate records for the cell therapy and the cytokine-vector therapy. A shared treatment episode identifier links the records while each record retains its own lot identifier, storage location, and receipt timestamp. Staff scan each container at handoff, and the system compares the scanned identifier with the assigned record.

Automated or data-driven variant

Automated scoring of mesothelin staining

Image analysis software takes a digitized mesothelin-stained tissue section and a tumor region marked by a reviewer. The software segments cells, applies a configured membrane staining threshold, and calculates the fraction of positive cells in each marked region. It exports the counts and a segmentation overlay for review.

Automated review of treatment records

An event processor reads timestamped administration records for the cell therapy and the cytokine-vector therapy. It groups events by treatment episode and displays the recorded order and elapsed time between administrations. It sends missing timestamps and duplicate entries to a review queue.

Specific version of a part

Completed administration before infusion

The preceding administration ends before the cell infusion begins. The treatment record captures the end time of the preceding administration and the start time of the cell infusion.

Cite aspatent.fyi, US 2026/0355268 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355268/, SHA-256 9d5f81fa854242358895039a411829319639e03f974786dd454c64cac6ad51c9
First published
Permanent addresshttps://patent.fyi/US20260355268/
Content fingerprint (SHA-256)9d5f81fa854242358895039a411829319639e03f974786dd454c64cac6ad51c9
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi